Escolar Documentos
Profissional Documentos
Cultura Documentos
AUTHOR QUERIES
DATE 10/15/2007
JOB NAME FTD
ARTICLE FTD200373
QUERIES FOR AUTHORS Skalli et al
THIS QUERY FORM MUST BE RETURNED WITH ALL PROOFS FOR CORRECTIONS
AU1) The citation of reference 45 is missing. Please insert it among the citations at the end of this or the next sentence (for
correct sequential order).
AU2) Please provide highest degree for authors Abdelhamid Zaid and Rachida Soulaymani.
REVIEW ARTICLE
TABLE 1. (continued ) The Most Common Herbal Medicines Reported in HerbDrug Interactions
Medical Plant Vernacular Name Drugs HerbDrug Interactions References
Momordicacharantia L. and Karela or bitter Diabetes mellitus drugs Blood glucose level effect 23, 101
Panaxginseng melon and ginseng
Lycium barbarum L. Lycium, mango Warfarin Anticoagulant effect 24, 103
(Solanaceae), Mangifera indica and papaya increased
L. (Anacardiaceae) and
Caricapapaya L. (Caricaceae)
Trigonellafoenum-graecum L. Fenugreek Glipizide, insulin and Excessive decrease 6062
other drugs that may lower of blood sugar levels
blood sugar levels
Heparin, ticlopidine and Bleeding 67
warfarin
Cyamopsistetragonoloba (L.) Gum guar and Digoxin Plasma digoxin 24
Taub. (Fabaceae) and wheat bran concentration decreased
Triticum spp. (Poaceae)
Boragoofficinalis L. and Borage and evening Anticonvulsants Seizure threshold lower 101
Oenotherabiennis L. primrose oil
(Onagraceae)
susceptibility varies from individual to individual. Drug during gestation or breast-feeding less dangerous than
transporters and metabolizing enzymes are the targets for drugs.6466 Few studies have assessed the use of HM in pre-
herbdrug interaction. Therefore, mechanism-based inhibition gnancy and the factors related to this use. Herbs are taken for
of cytochromes may provide an explanation for some reported venous insufficiency, lactation, gastroesophageal reflux, con-
herbdrug interactions. The best example is herbal interactions stipation, depression, and cutaneous problems and as caffeine
involving cytochrome P450 enzymes.5052 This large family substitutes. Also, HM may be taken for more serious disorders,
of enzymes has been shown to be involved in interactions particularly during the first trimester of pregnancy. Unfor-
between drugs and herbs. Pharmacokinetic interactions often tunately, women ignore that this is the most sensitive period for
occur as a result of changes in activity of drug-metabolizing serious adverse reactions and events.
and transporting proteins: cytochrome P450 isoenzymes In patients who are undergoing anticoagulant pharma-
and P-glycoprotein.53 Herbal medicines, when coadministered cotherapy, HM may interact with cardiovascular drugs.21
with prescription medicines, either induce or inhibit CYP Warfarin is the most common drug involved. Herbs such as
enzymes.54,55 This is exemplified by aristolochic acids con- fenugreek and Ferula communis L. can increase the risk of
tained in Aristolochia species plants undergoing reduction of bleeding (resulting in over-anticoagulation) when combined
the nitro group by hepatic cytochrome P450.56 Use of HM and with warfarin, heparin, and other anticoagulants, due to the
a prescription drug has the potential to decrease or increase the presence of coumarins.67 A case involving giant fennel has
effect of the drug.57 Eleutherococcus senticosus Rupt. & been reported to the Moroccan Pharmacovigilance Centre.
Maxim (Araliaceae), for example, increased the serum Ginkgo biloba L. has been reported to cause spontaneous
concentration of digoxin.58 However, pharmacological and bleeding, and it may interact also with anticoagulants and
clinical data are lacking on the majority of herbal products.59 antiplatelet agents.16 The risk appears to be higher among
Interactions may occur between different HM them- patients on chronic anticoagulation therapy.
selves. Many examples have been reported. One of these Another circumstance is when HM are used in the
concerns fenugreek (Trigonella foenum-graecum L., Fabaceae), preoperative period or in the context of anesthesia. In this
which may lower blood sugar levels,6062 and when it is used period, several drugs may be administered within a short
with other herbs that may alter blood sugar levels, such as period of time and anesthetists may not be aware that their
Momordica charantia L. (Cucurbitaceae), dose adjustments patients are taking HM. The use of herbal medications among
may be necessary. Fenugreek may also increase the risk of presurgical patients may have a negative impact on perioper-
bleeding when taken with Ginkgo biloba L. (Ginkgoacea) or ative patient care.68 Indeed, herbal remedies such as Allium
Allium sativum L. (Alliaceae). sativum L., Panax species, Ginkgo biloba L., Hypericum
It is particularly important to be cautious when taking perforatum L., and Valeriana officinalis L. (Valerianaceae) can
HM in certain circumstances, such as when the risk of adverse interact with drugs and lead to many complications such as
events and interactions is great and for some categories of prolonged or inadequate anesthesia, when they are taken in the
patients who may potentially be more vulnerable to such inter- preoperative period.69,70 This is probably caused by the
actions. During pregnancy and breast-feeding, surveys show, modulation of gamma-aminobutyric acid (GABA) neurotrans-
36% to 45% of pregnant women use herbal remedies20,63; this mission.7174 In this same period, Zingiber officinale Roscoe
is probably in the mistaken belief that HM as natural products (Zingiberaceae) and Aloe vera (Liliaceae) do not prevent
are safer than chemical drugs. This new thinking also applies postoperative nausea and vomiting, as perceived by some
to the use of HM in children. Women consider herbs taken patients.75,76 Another example is the use of Piper methysticum
Forst.f. (Piperaceae) in the perioperative period: the con- compound). The information for commercial herbal products
sumption of this herbal remedy (with anxiolytic and sedative may not always be complete, when HM may often contain
properties) has potential cardiovascular effects that could a combination of ingredients, some unknown, and of
manifest in the perioperative period. Kava seems to act unregulated quality.
through inhibition of sodium and calcium channels to conduct
direct decreases in systemic vascular resistance and blood Recommendations
pressure. However, no explanation of a mechanism for this The concurrent use of HM with prescribed drugs must take
effect has emerged from the literature. Kava may also produce into account their safety, efficacy, consistency, and
adverse neurologic effects (possibly related to its dopaminer- quality.9093 The safety of HM requires strict control of
gic antagonism)77,78 that may cause excessive periopera- the presence of adulterants, the dosage labeling, contra-
tive sedation.79 The pharmacokinetic and pharmacodynamic indications, manufacturing techniques, and a list of all
aspects of such interactions with this plant have not been ingredients. There is often no requirement to list each
studied systematically. However, pharmacodynamic herb ingredient of every herbal preparation on the label; more
drug interactions include potentiation of the sedative effect of significantly, only some of the ingredients are listed, but not
anesthetics by kava. On the other hand, kavalactones, the others that may be potentially harmful. Unfortunately, there
active component of kava extracts, have potential as inhibitors is also no requirement to precisely state the dose of active
of several enzymes of the CYP 450 system.80 So kava has the ingredients contained in herbal preparations. This should be
potential to interact with all drugs, even herbal products, which ensured through pharmacovigilance processes and strict
are metabolized by the CYP 450 enzymes. Other side effects regulatory controls.94,95
such as coagulopathies, water and electrolyte disturbances, There is a need for an adequate regulatory framework for
endocrine effects, and hepatotoxicity were observed, in rela- herbal products to effectively protect consumers and
tion with HM consumption.81 patients.
Among cancer patients, garlic, ginkgo, echinacea The clinical importance of herbdrug interactions depends
(Asteraceae), ginseng, St. Johns wort, and kava have been on many factors associated with the particular herb, drug,
reported as natural products that can cause potential pharma- and patient. HM should be appropriately labeled to alert
cokinetic interactions with anticancer drugs.82 HManticancer consumers to potential interactions when concomitantly
drug interactions can occur at the pharmaceutical, pharmaco- used with drugs.
dynamic, or pharmacokinetic level.83 Pharmacokinetic inter- The widespread use of HM in pregnancy and during the
actions are the most likely. They involve changes in absorption, breast-feeding period indicates an increased need for
distribution, metabolism, and excretion of the chemotherapeutic documentation about their safety and efficacy. Unfortu-
drug. It is estimated that HManticancer drug interactions are nately, both the efficacy and safety data are largely lacking
responsible for possible undertreatment seen in cancer patients. for the majority of HM, so they can not be recommended
Induction of drug-metabolizing enzymes leads to therapeutic during pregnancy and lactation.
failure with lower plasma levels of the anticancer drugs. ATP- Patients with cancer should avoid HM that may complicate
binding cassette drug transporters are also involved in HM- their cancer care.
anticancer drug interactions and can be one of the mechanisms During the preoperative evaluation, physicians should be
behind these interactions. Nuclear receptor (pregnane X familiar with the potential preoperative effects of the
receptor, the constitutive androstane receptor, and the vitamin commonly used herbal medications, in order to prevent,
D-binding receptor were recently identified) plays an important recognize, and treat potentially serious problems associated
role in the induction of metabolizing enzymes and drug with their use.
transporters. Kava-kava, ginseng, garlic and echinacea are It is important for health professionals, consumers, and
already implicated in these purposes.81 other interested stakeholder groups, including regulatory
In patients who use multiple medications, particularly authorities and suppliers of HM, to be aware of the side
elderly patients,84,85 polypharmacy and self-medication increase effects and drug interactions caused when herbal medicines
the possibilities of herbdrug interactions.86 are administered with conventional drugs. Patients should
Because of their presumed harmlessness, HM are often disclose their use of herbal medicines to their physicians and
taken by patients with chronic illness,8789 along with added pharmacists, who then will be aware of potential herbdrug
medication prescribed by physicians, and then are taken interactions. More effective communication between all
chronically. Use of both medicines simultaneously has a higher these partners is needed, and information must be accessible
potential for producing adverse events. In some situations, to all,96 which means that the responsibility of the safety
symptoms of disease or treatment are similar to those asso- information is shared. Various methods can be considered
ciated with HM adverse effects, and it is difficult to identify the for all relevant target audiences, such as involvement of the
problem.87 This could have an influence on quality of treatment. mass media and patient/consumer associations (including
Finally, some patients use crude forms of HM; in many translation into local languages where appropriate and
developing countries the source and quality of the medicines is essential for the public at large); education of health
unknown. HM are in common use and available in street professionals via the delivery of adverse- reaction bulletins
markets. Risks of interaction increase with the variability in or articles and meetings; and education about the impli-
packaging and labeling (eg, information on plant species, part cations for HM providers, academics, researchers/scientists,
of the plant utilized, type of preparation, type of marker and the pharmaceutical and herbal medicine industries.
Communication must be an inclusive network, well were lawfully ignored or classified as dietary supplements.
structured, collaborative, and adapted to the local and This exempts many herbal medications from safety and
cultural situation. efficacy requirements and regulation. On the other hand, more
It is imperative that physicians are aware of all medications, research and information are required (eg, preclinical, animal
both conventional and HM, that their patients are taking, in studies, premarketing controlled clinical trials, or postmarket-
order to provide the best care. This should be possible by ing surveillance) in order to guarantee the safety of patients
direct patient questioning. Physicians must regularly ask using HM.
their patients about their use of HM, particularly elderly
patients85 and those whose disease is not responding to
treatment as expected. This is important because adverse ACKNOWLEDGMENTS
reactions observed following use of conventional medicines The authors thank Mr. Bruce Hugman, communications
might in reality be due to HM or herbdrug interactions, consultant, Thailand, for his comments and suggestions
when physicians and other healthcare providers are unaware concerning this review.
of the extent of a patients self medication with alternative
therapies.97
Herbdrug interactions must be monitored. Scientific REFERENCES
1. Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment
recommendations on the use of HM and their coadminis- of report reliability. Br J Clin Pharmacol. 2001;52:587595.
tration with conventional therapy should be based on robust 2. De Smet PA. Herbal remedies. N Engl J Med. 2002;347:20462056.
scientific data rather than on the inadequate data of case 3. Fisher P, Ward A. Medicine in Europe: complementary medicine in
reports only. A thorough evaluation of the interaction of HM Europe. Br Med J. 1994;309:107111.
4. Barnes J, Abbot NC, Harkness EF, et al. Articles on complementary
with other medicines should be carried out; little attention medicine in the mainstream medical literature: an investigation of
has been paid to this issue to date. Current literature data are Medline, 1966 through 1996. Arch Intern Med. 1999;159:17211725.
unsubstantiated, with conclusions based on single or limited 5. Stupay S, Siversten L. Herbal and nutritional supplement use in the
reports. These data are generally insufficient to predict the elderly. Nurse Pract. 2000;25:5660.
incidence of herbdrug interactions. Thus, herbdrug inter- 6. Ernst E, Pittler MH. Risks associated with herbal medicinal products.
Wien Med Wochenschr. 2002;152:183189.
actions !need to be investigated through greater research, 7. World Health Organization. WHO guidelines on safety monitoring of
particularly by meta-analysis of prospective and clinical herbal medicines in pharmacovigilance systems. Geneva: World Health
studies using large population samples in order to avoid the Organization; 2004.
problems with individual susceptibility98 Prospective ran- 8. Ernst E. Herb-drug interactions: potentially important but woefully
under-researched. Eur J Clin Pharmacol. 2000;56:523524.
domized clinical trials assessing herbdrug interactions is an 9. Marcus DM, Grollman AP. Botanical medicines: the need for new
urgent need. regulations. N Engl J Med. 2002;347:20732076.
Exchange of data and research results among countries 10. Ikegami F, Fujii Y, Satoh T. Toxicological considerations of Kampo
must be encouraged and supported by improvement in medicines in clinical use. Toxicology. 2004;198:221228.
international conventions. Funds available for scientific and 11. Williamson EM. Interactions between herbal and conventional medi-
cines. Expert Opin Drug Saf. 2005;4:355378.
medical research should also be directed into clinical trials 12. Haller CA, Benowitz NL. Adverse cardiovascular and central nervous
of HM. system events associated with dietary supplements containing ephedra
The inclusion of information on HM as a source of therapy alkaloids. N Engl J Med. 2000;343:18331838.
will be needed in our academic programs. Pharmacological 13. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular
events temporally associated with ma huang, an herbal source of
aspects of phytotherapy should be included in the regular ephedrine. Mayo Clin Proc. 2002;77:1216.
medical and pharmacy curriculum99 14. Skalli S, Soulaymani R. A propos des produits Herbalife. LOfficinal.
Listing of safe combinations of HM and conventional drugs 2002;28:4.
can be provided as a guide to patient cares100 15. Chung MK. Vitamins, supplements, herbal medicines, and arrhythmias.
Cardiol Rev. 2004;12:7384.
16. Johns Cupp M. Herbal remedies: adverse effects and drug interactions.
Am Fam Phys. 1999;59:12391247.
CONCLUSION 17. Wittkowsky AK. Drug interactions update: drugs, herbs, and oral
Crude drugs and finished herbal products are often anticoagulation. J Thromb Thrombolysis. 2001;12:6771.
marketed as herbal medicines or dietary supplements for their 18. Chagan L, Ioselovich A, Asherova L, et al. Use of alternative
pharmacotherapy in management of cardiovascular diseases. Am J
claimed therapeutic effects and miraculous cures. Unfortu- Manag Care. 2002;8:270285.
nately, HM are not free of risk and interactions between these 19. Abebe W. Herbal medication: potential for adverse interactions with
products and prescription medications are an increasing analgesic drugs. J Clin Pharm Ther. 2002;27:391401.
concern and may have significant public consequences. 20. Ernst E. Serious psychiatric and neurological adverse effects of herbal
However, in most cases the claims have not been substantiated medicines: a systematic review. Acta Psychiatr Scand. 2003;108:8391.
21. Izzo AA. Herb-drug interactions: an overview of the clinical evidence.
and few HM have been subjected to double-blind, randomized, Fundam Clin Pharmacol. 2005;19:116.
placebo-controlled clinical trials. Their potential to cause 22. Yue QY, Bergquist C, Gerden B. Safety of St. Johns wort (Hypericum
adverse effects and interaction with conventional drugs are an perforatum). Lancet. 2000;355:576577.
understudied field of research. It is important to be aware that 23. Jiang M, Park M, Lee HC, et al. Antidiabetic agents from medicinal
plants. Curr Med Chem. 2006;13:12031218.
most HM fall outside of the regulatory framework and evi- 24. Izzo AA, Di Carlo G, Borrelli F, et al. Cardiovascular pharmacotherapy
dence is generally lacking on their safety, efficacy or standards and herbal medicines: the risk of drug interaction. Int J Cardiol. 2005;
of manufacture and control. Until now, herbal medications 98:114.
25. Izzo AA, Ernst E. Interactions between herbal medicines and prescribed 54. Delgoda R, Westlake AC. Herbal interactions involving cytochrome
drugs: a systematic review. Drugs. 2001;61:21632175. P450 enzymes: a mini review. Toxicol Rev. 2004;23:239249.
26. Henderson L, Yue QY, Bergquist C, et al. St. Johns wort (Hypericum 55. Guo LQ, Taniguchi M, Chen QY, et al. Inhibitory potential of herbal
perforatum): drug interactions and clinical outcomes. Br J Clin medicines on human cytochrome P450-mediated oxidation: properties of
Pharmacol. 2002;54:349356. umbelliferous or citrus crude drugs and their relative prescriptions. Jpn J
27. Kawaguchi A, Ohmori M, Tsuruoka S, et al. Drug interaction between Pharmacol. 2001;85:399408.
St. Johns and quazepam. Br J Clin Pharmacol. 2004;58:403410. 56. Zhou S, Koh HL, Gao y, et al. Herbal bioactivation: the good, the bad and
28. Mills E, Wu P, Johnston BC, et al. Natural health productdrug the ugly. Life Sciences. 2004;74:935968.
interactions: a systematic review of clinical trials. Ther Drug Monit. 57. Boullata J. Natural health product interactions with medication. Nutr
2005;27:549557. Clin Pract. 2005;20:3351.
29. Wang EJ, Barecki-Roach M, Johnson WW. Quantitative characterization 58. Madabushi R, Frank B, Drewelow B, et al. Hyperforin in St. Johns wort
of direct P-glycoprotein inhibition by St. Johns wort. J Pharm drug interactions. Eur J Clin Pharmacol. 2006;62:225233.
Pharmacol. 2004;56:123128. 59. Fong HH. Integration of herbal medicine into modern medical practices:
30. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. issues and prospects. Integr Cancer Ther. 2002;1:287293.
Drugs. 2005;65:12391282. 60. Sharma RD, Raghuram TC, Rao NS. Effect of fenugreek seeds on blood
31. Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection glucose and serum lipids in type I diabetes. Eur J Clin Nutr. 1990;44:
due to Saint Johns wort. Lancet. 2000;355:548549. 301306.
32. Hennessy M, Kelleher D, Spiers JP, et al. St. Johns wort increases 61. Raghuram TC, Sharma RD, Sivakumar B, et al. Effect of fenugreek seeds
expression of P-glycoprotein: implications for drug interactions. Br J on intravenous glucose disposition in non-insulin dependent diabetic
Clin Pharmacol. 2002;53:7582. patients. Phytother Res. 1994;8:8386.
33. Zhou W, Chai H, Lin HL, et al. Molecular mechanisms and clinical 62. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale
applications of ginseng root for cardiovascular disease. Med Sci Monit. Rosc) and fenugreek (Trigonella foenum graecum L.) on blood lipids,
2004;8:RA187192. blood sugar, and platelet aggregation in patients with coronary artery
34. Fattinger K, Meier-Abt A. Interactions of phytotherapeutic drugs, foods disease. Prostaglandins Leukot Essent Fatty Acids. 1994;56:379384.
and drinks with medicines. Ther Umsch. 2002;59:292300. 63. Nordeng H, Havnen GC. Use of herbal drugs in pregnancy: a survey
35. Janetzky K, Morreale AP. Probable interactions between warfarin and among 400 Norwegian women. Pharmacoepidemiol Drug Saf. 2004;13:
ginseng. Am J Health Syst Pharm. 1997;54:692693. 371380.
36. Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects 64. Mbura JS, Mgaya HN, Heggenhougen HK. The use of oral herbal
and drug interactions. Drug Saf. 2002;25:323344. medicine by women attending antenatal clinics in urban and rural Tanga
37. Yuan CS, Wie G, Dey L, et al. American ginseng reduces warfarins District in Tanzania. East Afr Med J. 1985;62:540550.
effect in healthy patients: a randomized, controlled trial. Ann Intern Med. 65. Hardy ML. Herbs of special interest to women. J Am Pharm Assoc. 2000;
2004;141:123126. 40:234242.
38. Izzo AA, Di Carlo G, Borrelli F, et al. Cardiovascular pharmacotherapy 66. Fugh-Berman A, Lione A, Scialli AR. Do no harm: avoidance of herbal
and herbal medicines: the risk of drug interaction. Int J Cardiol. 2006; medicines during pregnancy. Obstet Gynecol. 2005;106:409410.
110:93. 67. Samuels N. Herbal remedies and anticoagulant therapy. Thromb
39. Segal R, Pilote L. Warfarin interaction with Matricaria chamomilla. Can Haemost. 2005;93:37.
Med Assoc J. 2006;174:12811282. 68. Cheng B, Hung CT, Chiu W. Herbal medicine and anaesthesia. Hong
40. Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Kong Med J. 2002;8:123130.
Drug Metab Rev. 2004;36:57104. 69. Ang-Lee MK, Moss J, Yuan CS. Herbal Medicines and Perioperative
41. Galati G, OBrien PJ. Potential toxicity of flavonoids and other dietary Care. JAMA. 2001;286:208216.
phenolics: significance for their chemopreventive and anticancer 70. Pellerano P. Pharmacologic interactions of anesthesiologic importance. I.
properties. Free Radic Biol Med. 2004;37:287303. Interference between preoperative pharmacotherapy and anesthetic
42. De Smet PA. Health risks of herbal remedies. Drug Saf. 1995;13:8193. drugs. Acta Anaesthesiol. 1967;18:905911.
43. Bartels CL, Miller SJ. Herbal and related remedies. Nutr Clin Pract. 71. Skinner CM, Rangasami J. Preoperative use of herbal medicines:
1998;12:59. a patient survey. Br J Anaesth. 2002;89:792795.
44. Poppenga RH. Herbal medicines: potential for intoxication and 72. Hocking G, deMello WF. Preoperative use of herbal medicines. Br J
interactions with conventional drugs. Clin Tech Small Anim Pract. Anaesth. 2003;90:404.
2002;17:618. 73. Crowe S, Lyons B. Herbal medicine use by children presenting for
45. Singh SR, Levine M. Natural health product use in Canada: patterns of ambulatory anesthesia and surgery. Paediatr Anaesth. 2004;14:916919.
use and the risk of interactions with pharmaceuticals. Clin Pharmacol 74. Lin YC, Bioteau AB, Ferrari LR, et al. The use of herbs and
Ther. 2004;75:28. complementary medicine in pediatric preoperative patients. J Clin
46. Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of Anesth. 2004;16:46.
medication use in the ambulatory adult population of the United States: 75. Eberhart LH, Mayer R, Betz O, et al. Ginger does not prevent
the Slone survey. JAMA. 2002;287:337344. postoperative nausea and vomiting after laparoscopic surgery. Anesth
47. Makino T, Inagaki T, Komatsu KI, et al. Pharmacokinetic interactions Analg. 2003;96:995998.
between Japanese traditional medicine (Kampo) and modern medicine 76. Lynch GM. Herbal medicines in the United Kingdom. Anaesthesia.
(III). Effect of Sho-seiryu-to on the pharmacokinetics of azelastine 2003;58:1025.
hydrochloride in rats. Biol Pharm Bull. 2004;27:670673. 77. Connor KM, Davidson JR, Churchill LE. Adverse-effect profile of kava.
48. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the CNS Spectr. 2001;6:850853.
clinical implications. Clin Pharmacokinet. 1998;35:361390. 78. Patra KK, Coffey CE. Implications of herbal alternative medicine for
49. Ioannides C. Pharmacokinetic interactions between herbal remedies and electroconvulsive therapy. J ECT. 2004;20:186194.
medicinal drugs. Xenobiotica. 2002;32:451478. 79. Raduege KM, Kleshinski JF, Ryckman JV, et al. Anesthetic consid-
50. Zhou S, Gao Y, Jiang W. Interactions of herbs with cytochrome P450. erations of the herbal, kava. J Clin Anesth. 2004;16:305311.
Drug Metab Rev. 2003;35:3598. 80. Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug
51. Zhou S, Huang M, Xu A, et al. Prediction of herbdrug metabolic interactions with Kava (Piper methysticum Forst.f.). J Ethnopharmacol.
interactions: a simulation study. Phytother Res. 2005;6:464471. 2004;93:153160.
52. Brazier NC, Levine MA. Drugherb interaction among commonly used 81. Meijerman I, Beijnen JH, Schellens JH. Herbdrug interactions in
conventional medicines: a compendium for health care professionals. Am oncology: focus on mechanisms of induction. Oncologist. 2006;11:
J Ther. 2003;10:163169. 742752.
53. Butterweck V, Derendorf H, Gaus W, et al. Pharmacokinetic herbdrug 82. Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the
interactions: are preventive screenings necessary and appropriate? United States: potential adverse interactions with anticancer agents.
Planta Med. 2004;70:784791. J Clin Oncol. 2004;22:24892503.
83. Beijnen JH, Schellens JH. Drug Interactions in oncology. Lancet Oncol. 94. Barnes J. Pharmacovigilance of herbal medicines: a UK perspective.
2004;5:489496. Drug Saf. 2003;12:829851.
84. Yoon SJ, Horne CH. Herbal products and conventional medicines used 95. Menniti-Ippolito F, Mazzanti G, Firenzuoli F, et al. Pilot study for the
by community-residing older women. J Adv Nurs. 2001;33:5159. surveillance of adverse reactions to herbal preparations and dietary
85. Kales HC, Blow FC, Welsh DE, et al. Herbal Products and other supplements. Ann Ist Super Sanita. 2005;1:3942.
supplements: use by elderly veterans with depression and dementia and 96. Berry DC, Knapp PR, Raynor DK. Is 15% very common: informing
their caregivers. J Geriatr Psychiatry Neurol. 2004;17:2531. people about the risks of medication side effects. Int J Pharm Prac.
86. McCabe BJ. Prevention of food-drug interactions with special emphasis 2002;10:145151.
on older adults. Curr Opin Clin Nutr Metab Care. 2004;7:2126. 97. Woodward KN. The potential impact of the use of homeopathic and
87. Gozum S, U nsal A. Use of herbal therapies by older, community- herbal remedies on monitoring the safety of prescription products. Hum
dwelling women. J Adv Nurs. 2004;46:171178. Exp Toxicol. 2005;24:219233.
88. Iten F, Reichling J, Saller R. Adverse effects and interactions of 98. Aronson JK. Classifying drug interactions. Br J Clin Pharmacol. 2004;
phytotherapeutic drugs. Ther Umsch. 2002;59:283291. 58:343344.
89. Bressler R. Herbdrug interactions: interactions between Gingo biloba 99. Firenzuoli F, Gori L, Neri D. Fitoterapia clinica : opportunita` e
and prescription medications. Geriatrics. 2005;60:3033. problematiche. Ann Ist Super Sanita. 2005;41:2733.
90. Barnes J. Quality, efficacy and safety of complementary medicines: 100. Coxeter PD, McLachlan AJ, Duke CC, et al. Herb-drug interactions: an
fashions, facts and the future, part I: regulation and quality. Br J Clin evidence based approach. Curr Med Chem. 2004;11:15131525.
Pharmacol. 2003;55:226233. 101. Miller LG. Herbal medicinals: selected clinical considerations focusing
91. Barnes J. Quality, efficacy and safety of complementary medicines: on known or potential drugherb interactions. Arch Intern Med. 1998;
fashions, facts and the future, part II: efficacy and safety. Br J Clin 158:22002211.
Pharmacol. 2003;55:33140. 102. Valli G, Giardina E-G V. Benefits, adverse effects and drugs interactions
92. Choonara I. Safety of herbal medicines in children. Arch Dis Child. of herbal therapies with cardiovascular effects. J Am Coll Cardiol. 2002;
2003;88:10321033. 39:10831095.
93. Krochmal R, Hardy M, Bowerman S. Phytochemical assays of 103. Lam AY, Elmer GW, Mohutsky MA. Possible interaction between
commercial botanical dietary supplements. Evid Based Complement warfarin and Lycium barbarum L. Ann Pharmacother. 2001;35:1199
Alternat Med. 2004;1:305313. 1201.